Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients
NCT ID: NCT05383248
Last Updated: 2023-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2022-09-14
2023-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Reward - High Variance
High Reward - High Variance
Computerized reward learning task designed to increase reward responsiveness
High Reward - Low Variance
High Reward - Low Variance
Computerized reward learning task designed to have minimal effect on reward responsiveness
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High Reward - High Variance
Computerized reward learning task designed to increase reward responsiveness
High Reward - Low Variance
Computerized reward learning task designed to have minimal effect on reward responsiveness
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current diagnosis of Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)
* A score \< 7 on the Snaith-Hamilton Pleasure Scale (SHAPS) or \< 25 on the Positive Affect subscale from the Positive And Negative Affect Scale (PANAS)
* Sufficient proficiency in English language to understand and complete informed consent, interviews, questionnaires, and all other study procedures.
* Having normal or corrected vision
* Having normal or corrected hearing
Exclusion Criteria
* Endorsement of recent severe alcohol or substance use disorder (past 3 months).
* Inability to discontinue for 48 hours prior to scan any medications incompatible with measuring reliable/interpretable neural activity (e.g., e.g., benzodiazepines/beta-blockers, atypical anti-depressants, anxiolytics and sedative hypnotics, antipsychotics, and opioid analgesics)
* Being unsafe to undergo functional magnetic resonance imaging (fMRI), i.e., being pregnant, presence of non-removable metal in body, medical conditions that are incompatible with safe MRI (e.g., claustrophobia, inability to lie still on one's back for approximately 60 minutes; prior neurosurgery)
* Clinical conditions assessed by the interviewer that necessitate more imminent clinical care (e.g., active suicidal ideation): These criteria are in place so participants with these other, more several symptoms can be referred for appropriate mental health services.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katia Harle
Assistant Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Center for Functional Magnetic Resonance Imaging
La Jolla, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
309646-00001
Identifier Type: -
Identifier Source: org_study_id